The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations.

doi:10.1038/s41409-025-02765-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations.

Bone marrow transplantation - 1 Mar 2026

Abou Dalle Iman, Galimard Jacques-Emmanuel, Poire Xavier, Sanz Jaime, Huynh Anne, Kröger Nicolaus, Wagner-Drouet Eva Maria, Burns David, Eder Matthias, Lioure Bruno, Wu Depei, Mayer Jiri, Carlson Kristina, Stelljes Matthias, Collin Matthew, Aljurf Mahmoud, Nagler Arnon, Esteve Jordi, Ciceri Fabio, Bazarbachi Ali, Mohty Mohamad

Abstract excerpt

Mutations in the DNMT3A gene are not yet classified as a distinct prognostic group in the latest European Leukemia Net (ELN) 2022 genetic risk classification of AML. We analyzed 1888 adult AML patients with ELN 2022 intermediate- or poor-risk cytogenetics who received their first allo-transplant in first complete remission between 2015 and 2022. Among patients with cytogenetically normal AML, the triple-positive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA (Cytosine-5-)-Methyltransferases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Methyltransferase 3A

Share to fms-Like Tyrosine Kinase 3

Share to Karyotype

Share to Nucleophosmin

Share to Remission Induction

Share to Survival Rate

Share to Transplantation, Homologous

Source

Open in PubMed

Identifiers

PMID: 41437149
DOI: 10.1038/s41409-025-02765-1

Genes

DNMT3A
FLT3
NPM1
ELN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 17 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations.PMID 41437149Read ↗

Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWP.Semantic proximity Read ↗

Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutationsSemantic proximity Read ↗

Frequency and Impact of Somatic Co-occurring Mutations on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Multicenter Registry Analysis on Behalf of the EBMT ALWPSemantic proximity Read ↗

The Clinical Features and Prognosis of NPM1/FLT3-ITD/DNMT3A Triple-mutated Acute Myeloid LeukaemiaSemantic proximity Read ↗

FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort StudySemantic proximity Read ↗

Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party.Semantic proximity Read ↗

Comprehensive insights into AML relapse: genetic mutations, clonal evolution, and clinical outcomesSemantic proximity Read ↗

DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.Semantic proximity Read ↗

Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients.Semantic proximity Read ↗

Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a < 3log reduction of MRD2 predicted poor survival.Semantic proximity Read ↗

Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations.Semantic proximity Read ↗

DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.